ANX007-GLA-01
26 evidence topics · 4 sources
Objective
Registered primary, secondary, and exploratory objectives of the phase 1a study
Published objective of the first-in-human study
Company statement of the objectives of the glaucoma studies
Location and study date
Registry dates for the phase 1a study
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2018-03-23” |
| Primary completion (actual) | “2018-08-03” |
| Study completion (actual) | “2018-08-03” |
Study design
Registered design of the phase 1a study
Dose escalation and dose-limiting toxicity criteria
“In the dose-escalation phase Ia study, patients were enrolled into the lowest open cohort in an open-label manner and received a single dose of ANX007 at 1 of 3 dose levels (1 mg, 2.5 mg, or 5.0 mg), with cohort dose escalation in the absence of any dose-limiting toxicity. Dose-limiting toxicity criteria were defined as any of the following adverse events (AEs) occurring within 2 weeks after an IVT injection and considered to be related to ANX007: intraocular inflammation of at least grade 2, using the Standardization of Uveitis Nomenclature criteria, that was unresponsive to topical corticosteroid therapy; increase in IOP > 30 mm Hg that was unresponsive to topical or oral IOP-lowering medications; or loss of best corrected visual acuity of > 3 Snellen lines from baseline, excluding a transient loss immediately after IVT injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Published inclusion criteria for the phase 1a study
“In the phase Ia study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma on stable IOP-lowering medications, with a mean deviation of −3 to −18 dB on a reliable visual field test using the Humphrey field analyzer in the study eye, and an IOP < 21 mm Hg for ≥ 4 weeks before dosing, with no change to the IOP treatment regimen anticipated throughout study participation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria for both glaucoma studies
“For both studies, key exclusion criteria included intraocular inflammatory or infectious eye disease; uncomplicated cataract surgery < 3 months before injection; trabeculectomy, iridotomy, vitrectomy, or other incisional ocular procedures in the study eye that could affect drug distribution and excretion; and history of autoimmune or neurologic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered exclusion criteria for the phase 1a study
Treatment
Single-dose cohorts
“Nine patients with primary open-angle glaucoma (mean Humphrey visual field deviation between −3 and −18 decibels [dB]) were enrolled in phase Ia and received single doses of ANX007 (1.0 mg, n = 3; 2.5 mg, n = 3; or 5.0 mg, n = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravitreal injection procedure
“Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site. For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered outcomes of the phase 1a study
Follow-up and sampling in the phase 1a study
“In the dose-escalation phase Ia study, patients were followed for a total of 8 weeks for safety, tolerability, PK (unbound ANX007 serum concentration)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the single-dose study, samples for PK and PD analyses were obtained preinjection and 3 hours postinjection on day 1, and on days 2, 4, 8, and 15. Samples for the evaluation of serum ADAs were obtained preinjection, on study day 29, and at the follow-up visit on day 56.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants in the phase 1a study
Description of analysis sets
Safety and immunogenicity analysis population
“Pooled data are reported by dose level of ANX007 by study and non-study eye, where applicable. Patients who received ≥ 1 injection of ANX007 were assessed for safety and immunogenicity endpoints. The incidences of treatment-emergent AEs were tabulated by system organ class and preferred term, as well as by ocular or systemic intensity, or Common Terminology Criteria for Adverse Events grade, and by relationship to ANX007.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1a study by dose cohort
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events in the phase 1a study by dose cohort
Ocular and systemic adverse events after a single dose
“Eight ocular TEAEs were reported in the study eye, including ocular irritation, conjunctival hemorrhage, and conjunctival hyperemia, and 1 systemic TEAE was reported (sinusitis) which was not assessed to be related to ANX007 (Table 2). No ocular TEAEs were reported in the non-study eye for any patient. All AEs were mild in severity and resolved by the end of the study and there were no clinically significant laboratory results at any time during the on-therapy period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose-limiting toxicities were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety across both glaucoma studies
Intraocular pressure after a single dose
“Intraocular pressure returned to normal levels (defined as within 5 mm Hg of baseline or ≤ 21 mm Hg) at 30 minutes for all patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics
ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.